ACDC (medicine)
Rare genetic disorder causing arterial and joint calcification
| Arterial calcification due to deficiency of CD73 | |
|---|---|
| Synonyms | ACDC, CD73 deficiency |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Arterial calcification, joint stiffness, chronic pain |
| Complications | Peripheral artery disease, claudication, mobility impairments |
| Onset | Typically early to mid-adulthood |
| Duration | Lifelong |
| Types | |
| Causes | Mutation in the NT5E gene |
| Risks | Family history, genetic predisposition |
| Diagnosis | Genetic testing, radiographic imaging |
| Differential diagnosis | Pseudoxanthoma elasticum, vascular calcification, arteriosclerosis |
| Prevention | None |
| Treatment | Symptomatic; investigational use of adenosine or phosphatase inhibitors |
| Medication | Experimental therapies |
| Prognosis | Progressive, but not typically life-threatening |
| Frequency | Extremely rare |
| Deaths | Rare, related to cardiovascular complications |
Arterial calcification due to deficiency of CD73 (ACDC) is a rare genetic disorder characterized by abnormal calcium deposits in the arteries and joints, especially in the lower limbs. The condition results from mutations in the NT5E gene, which encodes the CD73 enzyme that plays a crucial role in purine metabolism and the regulation of vascular calcification.
History[edit]
Although patients with symptoms consistent with ACDC were first documented as early as 1914, the disorder remained poorly understood for nearly a century. It was not until 2011 that researchers were able to pinpoint the exact genetic cause: mutations in the NT5E gene that lead to a deficiency of CD73 enzyme activity.
Genetics[edit]
ACDC is caused by autosomal recessive mutations in the NT5E gene located on chromosome 6. This gene encodes the CD73 enzyme, which is involved in converting adenosine monophosphate (AMP) to adenosine. In individuals with ACDC, the deficiency in CD73 leads to a reduction in adenosine production, which normally plays a role in inhibiting vascular and soft tissue calcification.
Pathophysiology[edit]
In the absence of CD73 function, the molecular pathways that prevent calcium phosphate deposition in the vasculature are impaired. This results in progressive calcification of medium- and small-sized arteries and periarticular tissues, particularly in the hands, feet, and lower extremities.
Clinical presentation[edit]
The main symptoms of ACDC include:
- Progressive calcification of arteries and joints
- Claudication (pain during walking)
- Chronic pain in the lower limbs
- Joint stiffness and reduced range of motion
- In some cases, vascular insufficiency or peripheral artery disease
Diagnosis[edit]
ACDC diagnosis is confirmed by:
- Clinical evaluation of symptoms
- Imaging studies such as X-rays, CT scans, or MRI that reveal calcified arteries and joints
- Genetic testing to identify mutations in the NT5E gene
Treatment[edit]
There is currently no cure for ACDC. Treatment is symptomatic and may include:
- Pain management using analgesics
- Surgical intervention to remove calcified deposits or improve blood flow
- Physical therapy to preserve mobility and reduce stiffness
Experimental therapies[edit]
Recent molecular studies have demonstrated that treatment with adenosine or phosphatase inhibitors in laboratory models may reverse or prevent calcification associated with CD73 deficiency. These findings are preliminary but offer hope for future therapeutic development.
Prognosis[edit]
ACDC is a progressive condition that can significantly impact quality of life, particularly due to pain and reduced mobility. However, it is generally not life-threatening unless significant vascular complications develop.
Epidemiology[edit]
ACDC is an extremely rare disorder, with fewer than 20 families described in medical literature as of the 2020s. The true prevalence is unknown due to underdiagnosis and lack of awareness.
See also[edit]
External links[edit]
| Genetic disorders relating to deficiencies of transcription factor or coregulators | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NIH genetic and rare disease info[edit]
ACDC (medicine) is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - ACDC (medicine)
|
| Cardiovascular diseases | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This cardiovascular disease related article is a stub.
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


